Cleveland BioLabs, Inc. (CBLI) Receives an Increase in DoD Protectan CBLB502 Contract
More News related to CBLI
- Cleveland BioLabs Opens Enrollment of Second Safety Study for CBLB502
- Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential
- Cleveland BioLabs to Present at Merriman 6th Annual Investor Summit
- Cleveland BioLabs to Host Roundtable on Protectan CBLB502 for Acute Radiation Syndrome
- Cleveland BioLabs to Present at 8th Annual BIO Investor Forum
Cleveland BioLabs, Inc. (Nasdaq: CBLI) announced today that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Program Executive Office (CBMS-MITS JPEO) of The Department of Defense (DoD) incresed the ongoing contract for the developmental studies related to Protectan CBLB502. The contract, awarded in April 2008, will increase from $8.86 million to $9.59 million.
Related Categories
Corporate NewsStocks Mentioned
+0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
